BibTex RIS Cite

Overyan Sertoliform Endometrioid Karsinom: Olgu Sunumu

Year 2005, Volume: 8 Issue: 1, 28 - 31, 01.01.2005

Abstract

Sertoliform Endometrioid Karsinom (SEK) hemen hemen daima
postmenapozal hastalarda görülen bir epitelial over tümörü-
dür. Bu çal›flmada 67 yafl›nda, sa¤ adneksial alanda 7x6x5 cm’lik
kitle ve postmenapozal kanama ön tan›lar› ile bat›n s›v›s› örneklemesi,
Total Abdominal Histerektomi ve Bilateralooferektomi
uygulanmas› sonucu histolojisi SEK olarak tespit edilen, evresi 1c
olan bir hasta sunulmufltur. Yap›lan immunohistokimyasal çal›fl-
mada pansitokeratin, epitelial membran antijeni (AMA), ve Ca125
diffüz pozitif, vimentin hücrelerin % 30’unda pozitif, CEA
ve S-100 negatif, inhibin az say›da stromal hücre d›fl›nda negatifidi.
Adjuvan kemoterapide paklitaksel ve karboplatin kombinasyonu
kullan›ld›. Ovaryan Endometrioid Tümörlerin mikroskopik
düzeyde çeflitli varyantlar›ndan biri olan SEK gençlerde görülen
Sertoli Hücreli Tümörlerden ve Sertoli-Leydig Hücreli Tümörlerden
ay›rt edilmelidir. SEK iyi differansiye ve prognozu iyi olan
bir tümör olarak kabul edilir. Ayr›c› tan› ve hastal›¤›n yönetimi
literatür ›fl›¤›nda tart›fl›lmal›d›r

Year 2005, Volume: 8 Issue: 1, 28 - 31, 01.01.2005

Abstract

Sertoliform endometrioid carcinoma (SEC) is an epithelial
ovarian neoplasm occuring almost exclusively in post-menopausal
patients. In this study a 67-year-old patient who uderwent a
total abdominal washing taken for a right ovarian mass measuring
7x6x5 cm and postmenopausal bleeding is presented. Histology
revealed an SEC and stage 1c. Immunohistochemical study showed
that pancytokeratin, epithelial membrane antigen (EMA) and
Ca-125 were positive, vimentine was also positive in 30% of cells
and CEA, S-100 were negative and inhibin was negative except
some stromal cells. Carboplatin and paclitaxel were used in adjuvant
therapy. SEC being the microscopic variant of endometrioid
tumours must be distinguished from Sertoli cell tumours and
Sertoli-Leydig cell tumours which are encountered at a younger
age. SEC is considered a well-diferentiated endometrioid carcinoma
with a good prognosis. Differential diagnosis and management
of disease discussed in the light of the literatures

There are 0 citations in total.

Details

Other ID JA26TP76MA
Journal Section Case Report
Authors

Yasemin Yakut This is me

Selçuk Ayas This is me

İlkur Aköz This is me

Suna Cesur This is me

Ateş Karateke This is me

Publication Date January 1, 2005
Submission Date January 1, 2005
Published in Issue Year 2005 Volume: 8 Issue: 1

Cite

APA Yakut, Y., Ayas, S., Aköz, İ., Cesur, S., et al. (2005). Overyan Sertoliform Endometrioid Karsinom: Olgu Sunumu. Türk Jinekolojik Onkoloji Dergisi, 8(1), 28-31.
AMA Yakut Y, Ayas S, Aköz İ, Cesur S, Karateke A. Overyan Sertoliform Endometrioid Karsinom: Olgu Sunumu. TRSGO Dergisi. January 2005;8(1):28-31.
Chicago Yakut, Yasemin, Selçuk Ayas, İlkur Aköz, Suna Cesur, and Ateş Karateke. “Overyan Sertoliform Endometrioid Karsinom: Olgu Sunumu”. Türk Jinekolojik Onkoloji Dergisi 8, no. 1 (January 2005): 28-31.
EndNote Yakut Y, Ayas S, Aköz İ, Cesur S, Karateke A (January 1, 2005) Overyan Sertoliform Endometrioid Karsinom: Olgu Sunumu. Türk Jinekolojik Onkoloji Dergisi 8 1 28–31.
IEEE Y. Yakut, S. Ayas, İ. Aköz, S. Cesur, and A. Karateke, “Overyan Sertoliform Endometrioid Karsinom: Olgu Sunumu”, TRSGO Dergisi, vol. 8, no. 1, pp. 28–31, 2005.
ISNAD Yakut, Yasemin et al. “Overyan Sertoliform Endometrioid Karsinom: Olgu Sunumu”. Türk Jinekolojik Onkoloji Dergisi 8/1 (January 2005), 28-31.
JAMA Yakut Y, Ayas S, Aköz İ, Cesur S, Karateke A. Overyan Sertoliform Endometrioid Karsinom: Olgu Sunumu. TRSGO Dergisi. 2005;8:28–31.
MLA Yakut, Yasemin et al. “Overyan Sertoliform Endometrioid Karsinom: Olgu Sunumu”. Türk Jinekolojik Onkoloji Dergisi, vol. 8, no. 1, 2005, pp. 28-31.
Vancouver Yakut Y, Ayas S, Aköz İ, Cesur S, Karateke A. Overyan Sertoliform Endometrioid Karsinom: Olgu Sunumu. TRSGO Dergisi. 2005;8(1):28-31.